Floatz logo

Paclitaxel Poliglumex

Primary Peritoneal Carcinoma

GOG FoundationPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Primary Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Epirubicin
Roswell Park Cancer Institute
Phase 3BB
Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 3BB
Inno-206
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Paclitaxel Poliglumex is also rated in:

Ovarian Brenner TumorDormant
B
Indicative ·
56 / 100
View asset →
Malignant Ovarian Mixed Epithelial TumorDormant
B
Indicative ·
56 / 100
View asset →
Ovarian Undifferentiated CarcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →